150 related articles for article (PubMed ID: 37758837)
21. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
22. Optimizing D'Amico risk groups in radical prostatectomy through the addition of magnetic resonance imaging data.
Algarra R; Zudaire B; Tienza A; Velis JM; Rincón A; Pascual I; Zudaire J
Actas Urol Esp; 2014 Nov; 38(9):594-9. PubMed ID: 24791621
[TBL] [Abstract][Full Text] [Related]
23. Tumor contact with prostate capsule on magnetic resonance imaging: A potential biomarker for staging and prognosis.
Kongnyuy M; Sidana A; George AK; Muthigi A; Iyer A; Ho R; Chelluri R; Mertan F; Frye TP; Su D; Merino MJ; Choyke PL; Wood BJ; Pinto PA; Turkbey B
Urol Oncol; 2017 Jan; 35(1):30.e1-30.e8. PubMed ID: 27567248
[TBL] [Abstract][Full Text] [Related]
24. Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
Takeuchi N; Sakamoto S; Nishiyama A; Horikoshi T; Yamada Y; Iizuka J; Maimaiti M; Imamura Y; Kawamura K; Imamoto T; Komiya A; Ikehara Y; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2018 Aug; 16(4):e817-e829. PubMed ID: 29576444
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens.
Harmon SA; Gesztes W; Young D; Mehralivand S; McKinney Y; Sanford T; Sackett J; Cullen J; Rosner IL; Srivastava S; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Dobi A; Sesterhenn IA; Turkbey B
Radiology; 2021 Jun; 299(3):613-623. PubMed ID: 33847515
[TBL] [Abstract][Full Text] [Related]
26. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
28. External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy.
Ishizaki F; Hoque MA; Nishiyama T; Kawasaki T; Kasahara T; Hara N; Takizawa I; Saito T; Kitamura Y; Akazawa K; Takahashi K
Jpn J Clin Oncol; 2011 Nov; 41(11):1259-64. PubMed ID: 21940731
[TBL] [Abstract][Full Text] [Related]
29. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
[TBL] [Abstract][Full Text] [Related]
30. Identifying the Most Informative Prediction Tool for Cancer-specific Mortality After Radical Prostatectomy: Comparative Analysis of Three Commonly Used Preoperative Prediction Models.
Boehm K; Larcher A; Beyer B; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Heinzer H; Graefen M; Budäus L
Eur Urol; 2016 Jun; 69(6):1038-43. PubMed ID: 26272236
[TBL] [Abstract][Full Text] [Related]
31. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.
Roumiguié M; Beauval JB; Filleron T; Benoit T; Rischmann P; de la Taille A; Salomon L; Soulié M; Malavaud B; Ploussard G
BJU Int; 2014 Dec; 114(6b):E113-E119. PubMed ID: 24684584
[TBL] [Abstract][Full Text] [Related]
32. Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy.
Sandeman K; Eineluoto JT; Pohjonen J; Erickson A; Kilpeläinen TP; Järvinen P; Santti H; Petas A; Matikainen M; Marjasuo S; Kenttämies A; Mirtti T; Rannikko A
PLoS One; 2020; 15(7):e0235779. PubMed ID: 32645056
[TBL] [Abstract][Full Text] [Related]
33. PSA density does not improve predictive accuracy of the UCSF-CAPRA score.
Parker R; Bell A; Chang K; Greenberg S; Washington SL; Cowan JE; Carroll PR; Cooperberg MR
Prostate; 2023 Jul; 83(10):922-928. PubMed ID: 37078628
[TBL] [Abstract][Full Text] [Related]
34. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy.
Walz J; Joniau S; Chun FK; Isbarn H; Jeldres C; Yossepowitch O; Chao-Yu H; Klein EA; Scardino PT; Reuther A; Poppel HV; Graefen M; Huland H; Karakiewicz PI
BJU Int; 2011 Mar; 107(5):765-770. PubMed ID: 20875089
[TBL] [Abstract][Full Text] [Related]
35. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.
Gandaglia G; Ploussard G; Valerio M; Mattei A; Fiori C; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Moschini M; Zamboni S; Rakauskas A; Tian Z; Karakiewicz PI; De Cobelli F; Porpiglia F; Montorsi F; Briganti A
Eur Urol; 2020 Jun; 77(6):733-741. PubMed ID: 31547938
[TBL] [Abstract][Full Text] [Related]
36. Tumor localization by Prostate Imaging and Reporting and Data System (PI-RADS) version 2.1 predicts prognosis of prostate cancer after radical prostatectomy.
Fujimoto A; Sakamoto S; Horikoshi T; Zhao X; Yamada Y; Rii J; Takeuchi N; Imamura Y; Sazuka T; Matsusaka K; Ikeda JI; Ichikawa T
Sci Rep; 2023 Jun; 13(1):10079. PubMed ID: 37344491
[TBL] [Abstract][Full Text] [Related]
37. Prostate MRI percentage tumor involvement or "PI-RADS percent" as a predictor of adverse surgical pathology.
Ratnani P; Dovey Z; Parekh S; Sobotka S; Shukla D; Davis A; Roshandel R; Wagaskar V; Jambor I; Lundon DJ; Wiklund P; Kyprianou N; Menon M; Tewari A
Prostate; 2022 Jun; 82(9):970-983. PubMed ID: 35437769
[TBL] [Abstract][Full Text] [Related]
38. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
[TBL] [Abstract][Full Text] [Related]
39. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
40. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
